Publication:
Mst1/2 Signalling to Yap: Gatekeeper for Liver Size and Tumour Development

Thumbnail Image

Date

2011

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Nature Publishing Group
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Avruch, J, D Zhou, J Fitamant, and N Bardeesy. 2011. Mst1/2 signalling to yap: Gatekeeper for liver size and tumour development. British Journal of Cancer 104(1): 24-32.

Research Data

Abstract

The mechanisms controlling mammalian organ size have long been a source of fascination for biologists. These controls are needed to both ensure the integrity of the body plan and to restrict inappropriate proliferation that could lead to cancer. Regulation of liver size is of particular interest inasmuch as this organ maintains the capacity for regeneration throughout life, and is able to regain precisely its original mass after partial surgical resection. Recent studies using genetically engineered mouse strains have shed new light on this problem; the Hippo signalling pathway, first elucidated as a regulator of organ size in \(Drosophila\), has been identified as dominant determinant of liver growth. Defects in this pathway in mouse liver lead to sustained liver overgrowth and the eventual development of both major types of liver cancer, hepatocellular carcinoma and cholangiocarcinoma. In this review, we discuss the role of Hippo signalling in liver biology and the contribution of this pathway to liver cancer in humans.

Description

Keywords

liver cancer, hepatocellular carcinoma, cholangiocarcinoma, oval cells, Hippo, Rassf polypeptides, tumour suppressor pathway

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories